Table 2.
Comparison of diabetes-related characteristics of emerging adults with type 1 diabetes during the studied year stratified by the attainment of treatment targets.
| HbA1c, % (mmol/mol) | ≤7 (53) | >7 (53) | P |
|---|---|---|---|
| Patients, n (%) | 74 | 187 | |
| Age at diagnosis, median (IQR), years | 13.3 (10.1, 16.3) | 11.5 (8.8, 14.4) | 0.020 |
| Duration of diabetes, median (IQR), years | 11.4 (7.1, 16.1) | 11.0 (8.2, 15.3) | 0.877 |
| Autoimmune comorbidities, n (%) | 13 (17.6) | 33 (17.6) | 1 |
| Current treatment modality, n (%) | |||
| Multiple daily injections | 41 (55.4) | 112 (59.9) | 0.600 |
| Insulin pump | 33 (44.6) | 75 (40.1) | |
| Annual number of scheduled visits, median (IQR) | 3 (2, 4) | 4 (3, 5) | <0.001 |
| Annual number of clinic visits, median (IQR) | 2 (2, 3) | 3 (2, 3) | 0.043 |
| Attendance rate, median (IQR), percentage | 100 (67, 100) | 75 (50, 100) | 0.020 |
| Presence of hypoglycemic events, per 100 patient-years | 2.7 | 1.1 | 0.333 |
| Presence of diabetic ketoacidosis, per 100 patient-years | 1.4 | 1.1 | 0.847 |
| Presence of diabetes-related hospitalizations, per 100 patient-years | 2.7 | 2.2 | 0.789 |
| Microvascular complications, per 100 patient-years | 0.83 | 0.58 | 0.454 |
Data are presented as median and interquartile range (IQR) unless otherwise indicated. HbA1c, glycated hemoglobin; n, number; %, percentage. P ≤ 0.05 was considered significant.